Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kotelnikov, V. M.
Right arrow Articles by Preisler, H. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kotelnikov, V. M.
Right arrow Articles by Preisler, H. D.

Clinical Cancer Research, Vol 3, Issue 1 95-101, Copyright © 1997 by American Association for Cancer Research


ARTICLES

Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis

VM Kotelnikov, JS Coon 4th, S Mundle, S Kelanic, S LaFollette, IV Taylor S, J Hutchinson, W Panje, DD Caldarelli and HD Preisler
Rush Cancer Institute, Department of Pathology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612-3833, USA.

Deregulation of expression of the cell cycle regulator cyclin D1 (cD1) may be responsible for rapid proliferation of squamous cell carcinoma of the head and neck (SCCHN). We have studied the expression of cD1 in 46 SCCHNs using immunohistochemistry. Before biopsy, the patients received an in vivo infusion of iododeoxyuridine (IdUrd) for cell proliferation assessment. Additionally, the level of apoptosis was estimated using in situ end labeling (ISEL). Among 33 tumors, the proportion of cD1(+) cells varied from 0.5 to 51.3% (19.9 +/- 2.2%). Thirteen tumors did not express cD1. The fraction of S-phase (IdUrd-positive) cells was 26.3 +/- 1.8% in cD1(+) versus 20.0 +/- 2.4% in cD1(-) tumors (P = 0.06). The percentages of cD1(+) cells and of S-phase cells were not correlated (P = 0.37). Apoptosis was detected by ISEL in 15 of 33 tumors studied. ISEL-positive tumors contained a significantly higher proportion of cD1(+) cells (14.9 +/- 2.6%) than cD1(-) ones (7.9 +/- 2.8%; P = 0.03). There was a positive correlation between the percentage of cD1(+) cells and the degree of ISEL (r = 0.54; P < 0.001). In noninvolved oral mucosa, cD1(+) cells were located primarily in the suprabasal layers (29.3 +/- 3.8% versus 1.2 +/- 0. 2% in the basal layer). Only 23 of 44 mucosal specimens contained cD1(+) cells. All cD1(-) samples were proliferatively active and contained IdUrd-labeled cells. The percentage of cD1(+) cells in the oral epithelium from nontumor controls (uvula samples) was significantly higher than in the SCCHN group in both basal (2.4 +/- 0.4%; P = 0.008) and suprabasal (42.7 +/- 3.3%; P = 0.005) layers. Additionally, whereas in uvuli, cD1(+) cells were distributed evenly along the epithelial lining, in SCCHN samples the regions showing cD1 expression alternated with areas in which cD1 expression was undetectable. These data indicate that cD1 expression in SCCHN varies among tumors and is not correlated with cell proliferation. In noninvolved oral mucosa, cD1 expression differs from that in truly normal epithelium obtained from nontumor patients. A correlation between cD1 expression and the extent of ISEL positivity suggests a possible involvement of cD1 expression in the apoptotic pathways.


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. Shintani, M. Mihara, N. Terakado, Y. Nakahara, T. Matsumura, Y. Kohno, H. Ohyama, J. McBride, R. Kent, R. Todd, et al.
Reduction of p12DOC-1 Expression Is a Negative Prognostic Indicator in Patients with Surgically Resected Oral Squamous Cell Carcinoma
Clin. Cancer Res., September 1, 2001; 7(9): 2776 - 2782.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S.-C. Liu, S. Y. Zhang, J. S. Babb, J. A. Ridge, and A. J. P. Klein-Szanto
Image Cytometry of Cyclin D1: A Prognostic Marker for Head and Neck Squamous Cell Carcinomas
Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 455 - 459.
[Abstract] [Full Text]


Home page
Mol. Pathol.Home page
H K Williams
Molecular pathogenesis of oral squamous carcinoma
Mol. Pathol., August 1, 2000; 53(4): 165 - 172.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
R. J. Bova, D. I. Quinn, J. S. Nankervis, I. E. Cole, B. F. Sheridan, M. J. Jensen, G. J. Morgan, C. J. Hughes, and R. L. Sutherland
Cyclin D1 and p16INK4A Expression Predict Reduced Survival in Carcinoma of the Anterior Tongue
Clin. Cancer Res., October 1, 1999; 5(10): 2810 - 2819.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Brambilla, S. Gazzeri, D. Moro, S. Lantuejoul, S. Veyrenc, and C. Brambilla
Alterations of Rb Pathway (Rb-p16INK4-Cyclin D1) in Preinvasive Bronchial Lesions
Clin. Cancer Res., February 1, 1999; 5(2): 243 - 250.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1997 by the American Association for Cancer Research.